On this page · 4 sections→
Where the EU money came from
Funding by EU programme. Amounts are Exogenus Therapeutics SA's own share of each project, not the project's full budget.
- Horizon Europe€500k · 1 project
- Horizon 2020€165k · 2 projects
Projects
3 EU-funded projects, newest first. Exogenus Therapeutics SA led 3 of them as coordinator. Each links to the official record.
- EXO-OTOProtectCoordinator
Advancing a scalable and multifactorial exosome therapy to address the unmet needs of drug-induced hearing loss
Horizon Europe · 2026–2028 · Project on CORDIS ↗
€500ktheir share - TEXADCoordinator
TEXAD – Tailoring EXosomes for Autoimmune Diseases
Horizon 2020 · 2019–2020 · Project on CORDIS ↗
€115ktheir share - €50ktheir share
Fields it works in
Research fields recorded on its Horizon projects.
- DNA
- HIV
- autoimmune diseases
- biomolecules
- cell biology
- cells technologies
- commerce
- diabetes
- drug discovery
- implants
Is this your organisation?
Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.
Claim this profile →Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships.